Robert W. Baird Boosts Thermo Fisher Scientific (TMO) Price Target to $264.00

Thermo Fisher Scientific (NYSE:TMO) had its target price boosted by Robert W. Baird from $256.00 to $264.00 in a research note issued to investors on Thursday morning. Robert W. Baird currently has an outperform rating on the medical research company’s stock.

Several other equities research analysts have also recently commented on the stock. Zacks Investment Research raised shares of Thermo Fisher Scientific from a hold rating to a buy rating and set a $274.00 target price for the company in a research report on Monday, October 1st. Goldman Sachs Group cut shares of Thermo Fisher Scientific from a buy rating to a neutral rating in a research report on Monday, September 17th. UBS Group initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 9th. They issued a buy rating and a $295.00 target price for the company. Barclays raised their target price on shares of Thermo Fisher Scientific from $250.00 to $275.00 and gave the stock an overweight rating in a research report on Monday, September 24th. Finally, JPMorgan Chase & Co. reaffirmed an overweight rating and issued a $300.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 26th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Thermo Fisher Scientific has an average rating of Buy and a consensus target price of $261.45.

NYSE:TMO opened at $230.00 on Thursday. Thermo Fisher Scientific has a 12 month low of $181.51 and a 12 month high of $249.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.84 and a quick ratio of 1.11. The stock has a market capitalization of $92.64 billion, a PE ratio of 24.24, a P/E/G ratio of 1.67 and a beta of 1.12.



Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 24th. The medical research company reported $2.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.55 by $0.07. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. The firm had revenue of $5.92 billion during the quarter, compared to analysts’ expectations of $5.70 billion. During the same period last year, the company posted $2.31 EPS. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. As a group, research analysts forecast that Thermo Fisher Scientific will post 11.04 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Friday, September 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 2.1% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

In related news, CEO Marc N. Casper sold 125,520 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $247.50, for a total transaction of $31,066,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick M. Durbin sold 20,550 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $233.87, for a total transaction of $4,806,028.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 196,070 shares of company stock valued at $47,569,729. 0.49% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its holdings in Thermo Fisher Scientific by 3.2% in the second quarter. Dimensional Fund Advisors LP now owns 2,670,961 shares of the medical research company’s stock worth $553,246,000 after buying an additional 82,255 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Thermo Fisher Scientific by 1.7% in the second quarter. Janus Henderson Group PLC now owns 2,036,659 shares of the medical research company’s stock worth $421,880,000 after buying an additional 34,401 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Thermo Fisher Scientific by 3.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,566,563 shares of the medical research company’s stock worth $324,498,000 after buying an additional 46,519 shares during the last quarter. Findlay Park Partners LLP raised its holdings in Thermo Fisher Scientific by 8.9% in the second quarter. Findlay Park Partners LLP now owns 1,525,000 shares of the medical research company’s stock worth $315,889,000 after buying an additional 125,000 shares during the last quarter. Finally, Investec Asset Management LTD raised its holdings in Thermo Fisher Scientific by 5.5% in the second quarter. Investec Asset Management LTD now owns 1,463,481 shares of the medical research company’s stock worth $303,145,000 after buying an additional 75,675 shares during the last quarter. 86.07% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: How much money do you need to begin day trading?

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply